Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals

被引:22
作者
Briguori, C [1 ]
Testa, U
Colombo, A
Petrucci, E
Condorelli, G
Airoldi, F
Peschle, C
Condorelli, G
机构
[1] Univ Naples Federico II, Lab Intervent Cardiol, Naples, Italy
[2] Univ Naples Federico II, Dept Cardiol, Clin Mediterranea, Naples, Italy
[3] Univ Naples Federico II, Dept Biol Cellular & Mol Pathol, Naples, Italy
[4] Vita & Salute Univ, Sch Med, Hosp San Raffaele, Lab Intervent Cardiol, Milan, Italy
[5] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy
[6] Multimed Hosp, Milan, Italy
[7] Univ Roma La Sapienza, Rome, Italy
[8] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
关键词
D O I
10.1016/j.amjcard.2005.09.076
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We assessed (1) angiogenic factors in patients with stable angina and longstanding ( 24 months) total occlusion of a single coronary artery and (2) the relation between plasma levels of angiogenic factors and the development of collateral vessels as evaluated by coronary angiography. Plasma concentrations of vascular endothelial growth factor (VEGF(165)), fibroblast growth factor, placenta-derived growth factors (P1GFs), and hepatocyte growth factor were assessed in 96 patients with stable angina and longstanding (>= 24 months) total occlusion of a single coronary artery. According to coronary angiographic results, 18 patients had no visible collaterals (group 0), 21 patients had visible collaterals but no filling of the recipient epicardial vessel (group 1), and 57 patients showed filling (partial or complete) of the recipient epicardial vessel by collaterals (group 2). Plasma VEGF(165) and PIGF concentrations were higher in group 1 than in groups 0 and 2 (VEGF(165) 75 pg/ml, range 24 to 105, vs 23 pg/ml, range 15 to 29, and 19 pg/ml, range 10 to 41, respectively, F = 5.53, p = 0.006; P1GF 35 pg/ml, range 3.5 to 105, vs I pg/ml, range 1 to 38, and I pg/ml, range I to 5, respectively, F = 7.09, p = 0.008). Plasma VEGF(165) and P1GF levels were similar in groups 0 and 2. There was no significant difference in plasma levels of fibroblast and hepatocyte growth factor concentrations across the 3 groups. In conclusion, plasma levels of angiogenic growth factors differ among patients with stable angina pectoris and longstanding total coronary occlusion. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:472 / 476
页数:5
相关论文
共 26 条
  • [1] GRADING OF ANGINA-PECTORIS
    CAMPEAU, L
    [J]. CIRCULATION, 1976, 54 (03) : 522 - 523
  • [2] Mechanisms of angiogenesis and arteriogenesis
    Carmeliet, P
    [J]. NATURE MEDICINE, 2000, 6 (04) : 389 - 395
  • [3] Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice
    Couffinhal, T
    Silver, M
    Kearney, M
    Sullivan, A
    Witzenbichler, B
    Magner, M
    Annex, B
    Peters, K
    Isner, JM
    [J]. CIRCULATION, 1999, 99 (24) : 3188 - 3198
  • [4] Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1-to 3-vessel coronary artery disease
    Fleisch, M
    Billinger, M
    Eberli, FR
    Garachemani, AR
    Meier, B
    Seiler, C
    [J]. CIRCULATION, 1999, 100 (19) : 1945 - 1950
  • [5] INFLUENCE OF CORONARY COLLATERAL VESSELS ON MYOCARDIAL INFARCT SIZE IN HUMANS - RESULTS OF PHASE-I THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL
    HABIB, GB
    HEIBIG, J
    FORMAN, SA
    BROWN, BG
    ROBERTS, R
    TERRIN, ML
    BOLLI, R
    [J]. CIRCULATION, 1991, 83 (03) : 739 - 746
  • [6] Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia -: Phase II results of the Kuopio Angiogenesis Trial (KAT)
    Hedman, M
    Hartikainen, J
    Syvänne, M
    Stjernvall, J
    Hedman, A
    Kivelä, A
    Vanninen, E
    Mussalo, H
    Kauppila, E
    Simula, S
    Närvänen, O
    Rantala, A
    Peuhkurinen, K
    Nieminen, MS
    Laakso, M
    Ylä-Herttuala, S
    [J]. CIRCULATION, 2003, 107 (21) : 2677 - 2683
  • [7] Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion - Evidence for a dose-dependent effect
    Hendel, RC
    Henry, TD
    Rocha-Singh, K
    Isner, JM
    Kereiakes, DJ
    Giordano, FJ
    Simons, M
    Bonow, RO
    [J]. CIRCULATION, 2000, 101 (02) : 118 - 121
  • [8] Vascular endothelial growth factor in ischemia for vascular angiogenesis
    Henry, TD
    Annex, BH
    McKendall, GR
    Azrin, MA
    Lopez, JJ
    Giordano, FJ
    Shah, PK
    Willerson, JT
    Benza, RL
    Berman, DS
    Gibson, CM
    Bajamonde, A
    Rundle, AC
    Fine, J
    McCluskey, ER
    [J]. CIRCULATION, 2003, 107 (10) : 1359 - 1365
  • [9] Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
    Laham, RJ
    Chronos, NA
    Pike, M
    Leimbach, ME
    Udelson, JE
    Pearlman, JD
    Pettigrew, RI
    Whitehouse, MJ
    Yoshizawa, C
    Simons, M
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) : 2132 - 2139
  • [10] Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery - Results of a phase I randomized, double-blind, placebo-controlled trial
    Laham, RJ
    Sellke, FW
    Edelman, ER
    Pearlman, JD
    Ware, JA
    Brown, DL
    Gold, JP
    Simons, M
    [J]. CIRCULATION, 1999, 100 (18) : 1865 - 1871